Cybin is trading at $11.54, down 5.30%, during the August 31, 2026 session amid weakness across growth-oriented biotech stocks.
- No clear company-specific announcement has been identified; recent company announcements were dated August 18.
- Higher oil prices, renewed inflation concerns, and hawkish Federal Reserve messaging are pressuring risk assets.
- Cybin’s August 28 close was $12.18, following an 8.01% decline.